Screener
Tango Therapeutics TNGX Other operating expenses
Other operating expenses at other companies
Other financials
Where this comes from
Reported directly by Tango Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Tango Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-221656
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | 33,534 | 36,442 |
| General and administrative | 15,235 | 11,480 |
| Total operating expenses | 48,769 | 47,922 |
| Loss from operations | (48,769) | (42,530) |
| Other income: | ||
| Interest income | 2,177 | 1,614 |
| Other income, net | 1,079 | 1,074 |
Item 1. Financial Statements.
FAQ
- What is Tango Therapeutics's other operating expenses?
- Tango Therapeutics (TNGX) reported other operating expenses of $48.77M in Q1 2026.
- How has Tango Therapeutics's other operating expenses changed year-over-year?
- Tango Therapeutics's other operating expenses increased by 1.8% year-over-year, from $47.92M to $48.77M.
- What is the long-term trend for Tango Therapeutics's other operating expenses?
- Over 4 years (2021 to 2025), Tango Therapeutics's other operating expenses has grown at a 16.2% compound annual growth rate (CAGR), from $95.23M to $173.67M.
- What does other operating expenses mean?
- Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.
Ask your AI about Tango Therapeutics's other operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude